CTMC
- Company typePrivate
- Founded2022
- HeadquartersHouston, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
CTMC firmographics
Firmographics- Name
- CTMC
- Legal name
- Resilience Texas, LLC dba CTMC
- Website
- https://ctmc.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
CTMC industry classification
Industry- Product category
- Cell Therapy CDMO Services
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Cell Therapy CDMO (HLAGABAD)
- akta.pro secondary industries
- Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), CAR-T & TCR-T Therapies (HLAAABAC)
Keywords
Where CTMC is headquartered
LocationHeadquarters
- HQ city
- Houston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
CTMC business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Co-development Manufacturing Services: CTMC provides integrated development, manufacturing, and regulatory services to early-stage biotechs and academic groups through a co-development model. Services include process development, GMP manufacturing, regulatory strategy, clinical trial logistics, and quality services. The model is designed for capital efficiency, enabling biotech partners to focus capital on scientific innovation rather than infrastructure.
- Milestone-based Contracts with Equity Alignment: Business model innovation includes milestone-based contracts and in some cases equity alignment with biotech partners. This approach is critical in tough fundraising landscapes, allowing lean cell therapy teams to reach the clinic faster and more capital-efficiently.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels6 records
CTMC product offering
Product offeringCore offering
CTMC provides integrated cell therapy development, manufacturing, and regulatory services from its 60,000 sq. ft. GMP facility in Houston, Texas, specializing in autologous cell therapies including CAR-T, TCR-T, TIL, and NK cell therapies. Its 360° Solutions platform bundles process development, analytical services, GMP manufacturing, and regulatory expertise to help early-stage biotech and academic developers advance cell therapies from preclinical stage to clinical trials and commercial readiness.
Product overview
CTMC offers a unified platform called 360° Solutions comprising three integrated products: BioSolutions (comprehensive manufacturing capabilities from viral vector production to CAR-T, NK, and TIL therapies), BioExpertise (specialized cell therapy experience with proprietary reagents and methods), and BioInnovation (global access through the Network Alliance). The company provides end-to-end cell therapy development services including process development, GMP manufacturing, regulatory strategy, clinical trial logistics, and quality services. CTMC operates a patient-adjacent manufacturing model in the Texas Medical Center near MD Anderson Cancer Center, enabling efficient material transfer and seamless clinical coordination. The Network Alliance extends CTMC's reach globally through specialized training, educational programs, and manufacturing partnerships.
Differentiator
Problem solved
Functional benefit
Products and services
- 360° Solutions
- Network Alliance
- Biotech Partnerships (Co-Development Services)
- Academic Collaborations
- Autologous Cell Therapy GMP Manufacturing
Quantifiable outcome
- 8 INDs cleared with no delays since inception in 2022
- +2 more outcomes
Companies that use CTMC
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles3 records
CTMC technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
CTMC partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered flagship, core and minor.
- QIMR BerghoferflagshipQIMR Berghofer and CTMC announced strategic partnership through the CTMC Global Network Alliance to strengthen international collaboration in cell and gene therapy research, translation, workforce development, and advanced manufacturing. The partnership combines QIMR Berghofer's translational research and advanced therapeutics manufacturing capabilities, including its Q-Gen facility, with CTMC's model for cell therapy development, manufacturing, regulatory strategy, and clinical translation.
- Link Cell TherapiescorePartnership between Link Cell Therapies and CTMC is advancing next-generation CAR T therapies for solid tumours by combining dual-targeting logic-gated engineering with integrated manufacturing and clinical development to improve precision, safety and speed to trials. Link recently announced $60M Series A financing led by Johnson & Johnson.
- Einstein Hospital Israelita (Brazil)flagshipEinstein Hospital Israelita is the inaugural member of CTMC's Global Network Alliance. As the number one hospital in Latin America and recently named #17 Global Cancer Specialty Hospital by US News and World Report, Einstein is a premier leader of precision medicine. The partnership aims to democratize and accelerate cell therapies to cancer patients globally, starting with Latin America.
- SyenexcoreCTMC partnered with Syenex to advance scalability and efficiency of engineered T cell therapies. Through this collaboration, CTMC gains access to Syenex's bioengineering systems which provide significant improvement in gene delivery efficiency and manufacturing timelines.
- San Jacinto CollegeminorTransformative partnership between San Jacinto College and CTMC producing powerful results, equipping students for success in the fast-growing biomanufacturing sector while providing CTMC with ready-to-contribute talent.
- March BiosciencescoreStrategic alliance focused on development of March Biosciences' lead asset MB-105, an advanced cellular therapy currently in clinical studies at Baylor College of Medicine for treatment of relapsed T-cell cancers.
- KSQ TherapeuticscoreStrategic collaboration to expedite development of KSQ's two lead engineered tumor-infiltrating lymphocyte (eTIL) programs, KSQ-001EX and KSQ-004EX, both advancing toward clinical studies for treatment of solid tumors.
- Ori BiotechcoreOri Biotech and CTMC partnered to accelerate novel cell therapy delivery through development of industrial manufacturing processes. CTMC became a founding member of Ori's Preferred Partner Network (PPN), becoming Centers of Excellence for the IRO platform combining best-in-class technology with industry-leading development and manufacturing capabilities.
- Obsidian TherapeuticscoreMD Anderson and Obsidian Therapeutics collaborated with CTMC for novel TIL therapy OBX-115. FDA cleared IND application for Phase 1 clinical study in July 2022. Positive interim top-line clinical data announced December 2023 for advanced/metastatic melanoma.
- InvectyscoreStrategic collaboration for CAR T cell therapy development. CTMC and Invectys announced FDA clearance of IND application for anti-HLA-G CAR-T cell therapy (IVS-3001) for solid tumors in December 2022.
- National Resilience (Resilience)flagshipCTMC was established in 2022 as a joint venture between Resilience and MD Anderson Cancer Center. Resilience is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure treatments of today and tomorrow can be made quickly, safely, and at scale. Founded in 2020, Resilience has raised $2 billion to advance biopharmaceutical manufacturing.
- MD Anderson Cancer CenterflagshipCTMC is a joint venture with MD Anderson Cancer Center, one of the world's most respected centers focused on cancer patient care, research, education, and prevention. MD Anderson provides world-class clinical trial expertise, research faculty collaboration, and patient access within the Texas Medical Center.
Scale indicators8 records
Recent moves7 records
Expansion highlights6 records
CTMC competitors and assessment
Company assessmentDirect peers
- AGC Biologics: Global CDMO providing cell therapy, viral vector, and biologics manufacturing services. Comparable to CTMC in integrated cell therapy development and GMP manufacturing offering, though AGC operates multiple global sites including cell therapy capacity.
- Minaris Regenerative Medicine: Specialized cell therapy CDMO offering development, manufacturing, and testing services for cell and gene therapies. Closely comparable to CTMC in modality focus (CAR-T, TIL, stem cell therapies) and customer base of early-stage biotech developers.
- WuXi Advanced Therapies: Cell and gene therapy CDMO offering process development, GMP manufacturing, and testing for autologous and allogeneic therapies. Comparable to CTMC as an integrated cell therapy services provider targeting biotech innovators from preclinical through clinical.
- KBI Biopharma: CDMO offering cell therapy, microbial fermentation, and mammalian cell culture services. Comparable to CTMC in offering process development and GMP manufacturing for cell therapy developers, though KBI's portfolio spans multiple biologic modalities beyond cell therapy.
Emerging players
- Cellares: Emerging cell therapy manufacturing technology company developing automated, high-throughput cell therapy manufacturing platforms. Comparable as a next-generation cell therapy manufacturing enabler targeting biotech developers seeking scale, though Cellares focuses on automation hardware rather than integrated development services.
Broad incumbents
- Catalent (Cell Therapy): Major CDMO with cell therapy manufacturing capabilities including autologous and allogeneic platforms. Comparable to CTMC as a cell therapy contract manufacturer serving biotech developers, though Catalent's broader portfolio spans biologics, softgel, and oral dose forms.
- Thermo Fisher Scientific (Pharma Services): Diversified life sciences company with cell therapy manufacturing services through its Pharma Services segment. Comparable to CTMC as a contract manufacturer for cell therapies, though Thermo Fisher operates at massive scale across the full pharma services value chain.
- Resilience: National Resilience is one of CTMC's JV parents and a broader biopharmaceutical manufacturing network. Comparable as a cell therapy and biologics manufacturing organization, though Resilience operates at platform scale well beyond CTMC's specialized cell therapy focus.
- Charles River Laboratories (Cell & Gene Therapy): Established CRO/CDMO with cell and gene therapy manufacturing and testing capabilities. Comparable to CTMC in cell therapy CDMO offering, though Charles River's broader portfolio spans discovery, safety, and clinical services across multiple modalities.
- Lonza (Cell & Gene Technologies): Global CDMO leader with dedicated cell and gene therapy manufacturing services across viral vectors, autologous and allogeneic cell therapies. Comparable as a specialized cell therapy CDMO serving similar biotech customers, though Lonza operates at much larger scale with multi-site global capacity.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
CTMC social profiles
Digital presenceCTMC financial estimates
Financial estimateRevenue estimate
Valuation estimate
CTMC leadership team
Management profileNumber of profiles
Profiles11 records
CTMC funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CTMC M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CTMC
What does CTMC do?
CTMC provides integrated cell therapy development, manufacturing, and regulatory services from its 60,000 sq. ft. GMP facility in Houston, Texas, specializing in autologous cell therapies including CAR-T, TCR-T, TIL, and NK cell therapies. Its 360° Solutions platform bundles process development, analytical services, GMP manufacturing, and regulatory expertise to help early-stage biotech and academic developers advance cell therapies from preclinical stage to clinical trials and commercial readiness.
Is CTMC a public or private company?
CTMC is a private company. It is classified as corporate owned and is currently operating.
When was CTMC founded?
CTMC was founded in 2022. It employs 101 to 250 people.
Where is CTMC based?
CTMC is headquartered in Houston, United States, in the North America region.
How does CTMC make money?
Two revenue lines are on record. Co-development Manufacturing Services are the primary driver. The others are milestone-based Contracts with Equity Alignment.
Who are CTMC's main competitors?
Direct peers on record are AGC Biologics, Minaris Regenerative Medicine, WuXi Advanced Therapies and KBI Biopharma. Cellares is listed as an emerging player. Broad incumbents are Catalent (Cell Therapy), Thermo Fisher Scientific (Pharma Services), Resilience, Charles River Laboratories (Cell & Gene Therapy) and Lonza (Cell & Gene Technologies).
Does CTMC have an API?
No public API is recorded for CTMC.
What industry is CTMC in?
CTMC's product category is Cell Therapy CDMO Services. Its primary akta.pro industry code is HLAGABAD, Cell Therapy CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325414 and its SIC code is 8731.